文献速递脊柱关节炎

抗炎治疗对脊柱关节炎抑郁症状的影响:药物类型是否重要?

The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

基于ASAS健康指数验证研究观察性数据,304例脊柱关节炎患者分别在起始NSAIDs、csDMARDs或TNF抑制剂后评估HADS-D变化。所有治疗组抑郁症状均显著改善;多变量回归未校正疾病活动度时,起始TNF抑制剂较NSAIDs与抑郁症状更大改善相关(β=-1.27,95%CI -2.23,-0.32),校正ASDAS/BASDAI后该关联减弱。

要点

  • 活动性SpA治疗可同时改善抑郁症状,所有治疗组HADS-D均显著改善。
  • 未校正疾病活动度时,TNF抑制剂较NSAIDs与抑郁症状改善更大相关,校正后减弱。
  • csDMARDs与NSAIDs对HADS-D的影响无差异。

核心结论

  • 治疗活动性SpA也可改善抑郁症状。
  • 尤其在axSpA中,TNF抑制剂效果大于NSAIDs,这主要由对疾病活动度更强的效果解释。
  • 未发现CRP介导的炎症与SpA抑郁症状之间存在直接联系的证据。

研究设计与样本

  • 采用ASAS健康指数验证研究的观察性数据。
  • 患者在基线和起始NSAIDs/csDMARDs/TNF抑制剂后接受评估。
  • 共纳入304例患者,102/45/157例分别起始NSAIDs/csDMARDs/TNF抑制剂,260例(85%)/44例(15%)为轴向/外周SpA。
  • 抑郁症状采用医院焦虑抑郁量表抑郁亚量表(HADS-D;0-21,最佳-最差)评估。
  • 采用方差分析和多变量回归分析比较各治疗间HADS-D自基线的变化。

主要发现

  • 基线平均HADS-D为6.9(s.d. 4.2);126例(42%)可能存在抑郁(HADS-D≥8),66例(22%)很可能存在抑郁(HADS-D≥11)。
  • 随访时所有治疗组抑郁症状均显著改善。
  • 未校正疾病活动度指标的多变量回归中,起始TNF抑制剂较NSAIDs与抑郁症状更大改善相关(β=-1.27,95%CI -2.23,-0.32),且随访时可能抑郁的比值更低(OR 0.47,95%CI 0.23,0.94)。
  • 额外校正疾病活动度(ASDAS/BASDAI)后该关联减弱,但校正CRP后未减弱。
  • csDMARDs与NSAIDs对HADS-D的影响无差异;药物类别间结果在axSpA中得到证实,但在外周SpA中较不明确。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effect of pharmacological treatment of SpA on depressive symptoms and explore whether this effect differs between drug classes. METHODS: Data from the observational Assessment of SpondyloArthritis international Society Health Index Validation Study were used. Patients were assessed at baseline and after initiation of NSAIDs/conventional synthetic DMARDs (csDMARDs)/TNF inhibitors (TNFis). Depressive symptoms were assessed with the Hospital Anxiety and Depression Scale depression subscale [HADS-D; 0-21 (best-worst)]. Covariables included demographics and disease characteristics, including disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)/BASDAI]. The change in HADS-D from baseline was compared between treatments (NSAIDs/csDMARDs/TNFis) with analysis of variance and multivariable regression analysis. RESULTS: A total of 304 patients were included; 102/45/157 initiated NSAIDs/csDMARDs/TNFis and 260 (85%) / 44 (15%) had axial/peripheral SpA. At baseline, the mean HADS-D was 6.9 (s.d. 4.2); 126 (42%) were possibly depressed (HADS-D ≥8) and 66 (22%) were probably depressed (HADS-D ≥11). At follow-up, depressive symptoms significantly improved in all treatment groups. In multivariable regression without disease activity measures, initiating TNFis compared with NSAIDs was associated with greater improvement in depressive symptoms [β = -1.27 (95% CI -2.23, -0.32)] and lower odds of possible depression at follow-up [odds ratio 0.47 (95% CI 0.23, 0.94)]. This association was attenuated after additional adjustment for disease activity (ASDAS/BASDAI) but not CRP. csDMARDs did not differ from NSAIDs regarding their effect on HADS-D. Between-drug class results were confirmed in axial SpA (axSpA), although less clear in peripheral SpA. CONCLUSION: Treatment of active SpA also improves depressive symptoms. Especially in axSpA, TNFis have a greater effect than NSAIDs, which is mainly explained by a stronger effect on disease activity. We found no evidence for a direct link between CRP-mediated inflammation and depressive symptoms in SpA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Webers C, Kiltz U, Braun J, et al. The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter? Rheumatology (Oxford). 2023. PMID: 36205588. doi:10.1093/rheumatology/keac580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。